

1 **Performance of Gazelle COVID-19 point-of-care test for detection of nucleocapsid antigen**  
2 **from SARS-CoV-2**

3

4 **Running Title: Point-of-care diagnostic for Covid-19**

5

6 Amrish Mehta<sup>1</sup>, Bri Spencer<sup>2</sup>, Ashok Garg<sup>3</sup>, Pradeep Kalmorge<sup>4</sup>, Raúl A. Ocasio Gonzalez<sup>5</sup>,  
7 Kate Taussig<sup>5</sup>, Ryan R. Fortna<sup>2\*</sup>

8

9 **Affiliations:**

10 <sup>1</sup>Apple Diagnostics, Ghatkopar, Mumbai

11 <sup>2</sup>Northwest Laboratory, Bellingham, WA, USA

12 <sup>3</sup>Acu-MDx Laboratory and Research Center Pvt. Ltd Diagnostics, Ghatkopar West, Mumbai

13 <sup>4</sup>Bio Diagnostics Laboratory, Pune

14 <sup>5</sup>Hemex Health, Portland, USA

15

16

17 **Correspondence:** \*Ryan R. Fortna

18 Email: Ryan.Fortna@nwpathology.com

19 3548 Meridian Street, Suite 101

20 Bellingham, WA 98225

21 (360) 527-4580

22

23 **Abstract Word count: 148**

24

25 **Body of the Text Word Count: 2090**

26

27

28

29

30

31

32 **Abstract:**

33

34 SARS-CoV-2 antigen assays offer simplicity and rapidity in diagnosing COVID-19. We assessed  
35 the clinical performance of Gazelle COVID-19 test, a fluorescent lateral flow immunoassay with  
36 an accompanying Reader utilizing image-recognition software for detection of nucleocapsid  
37 antigen from SARS-CoV-2. We performed a prospective, operator-blinded, observational study  
38 at 2 point-of-care (POC) sites. Nasal swab specimens from symptomatic patients were tested  
39 with Gazelle COVID-19 test and real-time polymerase chain reaction (RT-PCR) assay. Overall,  
40 data from 1524 subjects was analyzed, and 133 were positive by RT-PCR. Mean (range) age of  
41 participants was 34.7 (2-94) years and 570 (37.4%) were female. The sensitivity and the  
42 specificity of the Gazelle COVID-19 test were 96.3% and 99.7%. The PPV of Gazelle COVID-  
43 19 test was 97.0%, NPV 99.6%, and accuracy 99.4%. In POC settings, Gazelle COVID-19 test  
44 had high diagnostic accuracy for detection of SARS-CoV-2 in nasal swab samples of  
45 symptomatic subjects suspected of COVID-19.

46

47 **Keywords:** COVID-19; SARS-CoV-2; immunoassay, RT-PCR, detection

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93

## **INTRODUCTION**

The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic health emergency [1]. The high rate of community and institutional transmission [2] of SARS-CoV-2 infection underscores the need for rapid and accurate detection of active infection. In a survey of unmet needs for COVID-19 tests in health and social care settings, hospitals identified COVID-19 testing as the second highest unmet need, with the greatest priority being a test for symptomatic patients presenting to hospitals for infection control [3]. Studies have shown that of the various steps required in the process of testing and diagnosing an active infection, minimizing testing delay had the largest impact on reducing onward transmissions [4, 5]. Current diagnostic tests for the SARS-CoV-2 detect either nucleic acid or antibody of viral protein [6]. Several molecular assays based on reverse transcriptase polymerase chain reaction (RT-PCR) have been developed to detect and quantify SARS-CoV-2 RNA. However, COVID-19 patients can continue to shed viral RNA well beyond clinical recovery and positive RT-PCR does not necessarily indicate infectiousness [7]; RT-PCR testing detects residual genome, and a test of actual infectivity (viable virus) is needed. Furthermore, RT-PCR is expensive, has a relative long turn-around-time, require trained personnel, and is often available only in laboratory set-ups that provide centralized services. In February 2020, WHO identified rapid testing with point-of-care (POC) diagnostics as a number one priority to address the COVID-19 pandemic [8] and the US Food and Drug Administration (FDA) permitted licensed laboratories to report in-house developed SARS-CoV-2 diagnostic tests [9]. The Gazelle COVID-19 Test is a fluorescent lateral flow immunoassay (FIA) for the qualitative detection of nucleocapsid antigen from SARS-CoV-2. The Gazelle platform includes a Reader which is capable of reading both colorimetric and certain fluorescent lateral flow assays and is adapted from the commercially available hemoglobin variant reader, using derived image-recognition software [10]. Here, we present the results from an observational study to assess the diagnostic performance of Gazelle Covid-19 Test, compared to RT-PCR.

94 **METHODS**

95 *Study Design and Population*

96 We conducted a prospective, observational study to determine the diagnostic performance of  
97 Gazelle Covid-19 Test, compared to RT-PCR. The study was conducted in two different regions  
98 from 23 August 2021 through 12 November 2021. The first site was at Northwest Laboratory's  
99 COVID-19 drive-through screening site located at the Bellingham Airport, Washington, USA  
100 and the second one was at Bio Diagnostics laboratory, Pune and Acu-MDx Laboratory and  
101 Research Center Pvt. Ltd Diagnostics Lab, Mumbai, India. The objective of the study was to  
102 assess Gazelle COVID-19 Test performance (positive percent agreement [PPA] and negative  
103 percent agreement [NPA]) in comparison to RT-PCR using dual mid-turbinate nasal swab  
104 samples from symptomatic subjects (within five days of onset of symptoms) at point of care.

105

106 Participants were recruited, screened, and enrolled by the Investigator's team at each site as per  
107 the inclusion and exclusion criteria pre-specified in the study protocol. All consecutive patients  
108 who visited the facilities for a Covid test and who met inclusion criteria were enrolled in the  
109 study and informed consent was obtained. Operators of the Gazelle COVID-19 Test and the RT-  
110 PCR test were blinded to the results on the different test platform. Additionally, operators tested  
111 a set of blinded, contrived samples to ensure consistency of performance between operators at  
112 the Bellingham location

113

114 All methods were performed in accordance with the relevant guidelines and regulations. This  
115 paper was drafted according to STROBE and STARD guidelines to ensure the quality of  
116 reporting [11, 12].

117

118 *Sample Collection*

119 Direct human nasal swab samples were collected from symptomatic subjects and tested  
120 immediately on Gazelle at each site. The swab for RT-PCR was collected immediately before the  
121 swab for the Gazelle test. The swabs for RT-PCR were stored at ambient temperature in Brooks  
122 tubes [should probably provide the item number here] with 0.9% sterile saline according to  
123 Northwest Laboratories protocol, then transported to the laboratory at the end of the day for

124 testing within 24 hours of collection. The swabs collected in India were also stored in sterile  
125 saline and tested within 24 hours of collection.

126

### 127 *Gazelle Covid-19 Test*

128 Gazelle COVID-19 (Figure 1) is a fluorescent lateral flow immunoassay and accompanying  
129 Reader intended for the detection of nucleocapsid antigen from SARS-CoV-2 in nasal swab  
130 specimens who are suspected of COVID-19 by their healthcare provider within 5 days of  
131 symptom onset. The Gazelle COVID-19 Test detects COVID-19 nucleocapsid protein in dual  
132 nasal mid-turbinate swab specimens. The Reader is equipped with LEDs and is capable of  
133 reading both colorimetric and certain fluorescent lateral flow assays.

134

### 135 *RT-PCR Procedure*

136 *Northwest Laboratories, USA:* Confirmation of COVID-19 status was done by using the  
137 TaqPath™ COVID-19 Combo Kit (ThermoFisher Scientific, Pleasanton, CA, USA - Document:  
138 MAN0019181 Rev. A.0. March 12, 2020.). RT-PCR assays and analysis were performed  
139 following the instructions of the manufacturer using Northwest Laboratory's 7500 Fast Real-  
140 Time PCR System Thermocycler (Applied Biosystems, CA, USA). This system was validated  
141 via correlation studies with the Washington State Public Health Laboratory using a test system  
142 authorized for emergency use by the FDA. Briefly, the conditions of the thermal profile  
143 followed several specific steps: (1) 25°C for 2 min; (2) 53°C for 10 min; (3) 95°C for 2 min (4)  
144 40 cycles at 95°C for 3 s, and 60°C for 30 s. According to the instructions of the manufacturer in  
145 N-target, the Ct value <37 or two replicates with Ct values of 38 were considered positive; Ct  
146 values >39 were considered negative. An exogenous control was included in all reactions using  
147 primers and probe specifically directed at MS2-Phage genomic RNA, obtained from TaqPath™  
148 COVID-19 Combo Kit. Furthermore, positive, negative, and non-template controls were  
149 included in each run. A Ct value <30 in the positive control and no Ct values in negative and  
150 non-template controls were considered to validate runs.

### 151 *Bio Diagnostics laboratory and Acu-MDx Laboratory and Research Center Pvt. Ltd*

152 *Diagnostics, India:* Confirmation of COVID-19 status was done by using the Taq Path Covid  
153 RT-PCR kit (Applied Biosystems; Document No: 100033995 Rev. B.0.Pub No. MAN0014069).  
154 RT-PCR assays and analysis were performed following the instructions of the manufacturer

155 using Quantstudio 5 RT-PCR Instrument (Applied Biosystems). Briefly, the conditions of the  
156 thermal profile followed several specific steps: (1) 25°C for 2 min; (2) 53°C for 10 min; (3) 95°C  
157 for 2 min (4) 40 cycles at 95°C for 3 s, and 60°C for 30 s. According to the instructions of the  
158 manufacturer in N-target, the Ct value <35; Ct values >35 were considered negative.

159

#### 160 *Data collection and Statistical Analysis*

161 Operators of the Gazelle test were the employees certified by the respective laboratories at taking  
162 nasal swabs with no formal training. The operators were provided the Instructions for Use (IFU).  
163 No additional training on the Gazelle test was provided to the operators. Following Gazelle  
164 COVID-19 Test, data from the Gazelle Reader was sent to Hemex to be analyzed by the Gazelle  
165 Covid-19 algorithm. RT-PCR results were recorded at the testing laboratory according to its  
166 procedures. They were also recorded in a Google spreadsheet provided by the sponsor. Other  
167 Case Report Form information was entered by the test site and then copied into the Google  
168 spreadsheet.

169

170 All test results recorded in the spreadsheets were reviewed and verified for completeness and  
171 entry accuracy by the Investigator and Hemex Monitor (Hemex employee responsible for  
172 monitoring study quality). Test results were verified daily to ensure they were complete and error  
173 free.

174

175 The diagnostic performance Gazelle Covid-19 test was assessed using sensitivity, specificity,  
176 positive predictive value (PPV) and negative predictive value (NPV). Data was analyzed for  
177 sensitivity or PPA (i.e., the probability that the assay will be positive when the comparator assay  
178 is positive; sensitivity = comparator positive (TP)/(TP + false negative [FN]) ×100%) and  
179 specificity or NPA (i.e., the probability that the assay will be negative when the comparator  
180 assay is negative; specificity = comparator negative (TN)/(TN + (false positive [FP]) ×100%).

181

## 182 **RESULTS**

183 A total of 1090 potential participants were screened in India and 458 were screened at  
184 Bellingham site in the United States. Patient screening and enrolment details are presented in the  
185 flow chart (Figure 2).

186 Overall, data from 1486 participants was analyzed. Mean (range) age of study participants from  
187 the Bellingham site was 32.8 (2-90) years and 250 (58.4%) were female. Mean (range) age of  
188 study participants from India was 35.5 (4-94) years and 304 (28.7%) were female. A total of 133  
189 tests were RT-PCR positive and 1353 were RT-PCR negative. Gazelle Test results and  
190 performance in comparison to RT-PCR is presented in **Table 1 and Table 2**, respectively.

191  
192 A total of 23 operators performed 428 tests (range, 1-59) at the Bellingham site. As a quality  
193 control measure, consistency of performance among test operators was also assessed at the  
194 Bellingham site. A total of 24 Gazelle tests (4 Gazelle tests per sample) were run across 6  
195 contrived samples (A, B, C D, E, and F). Each of the 4 operators assessed ran one Gazelle test on  
196 each of the 6 contrived samples. Three of the contrived samples were negative (samples A, D,  
197 and F), and 3 were <2x limit of detection positive (samples B, C, and E). The concentration of  
198 the positive samples was 10-50% tissue culture infective dose/mL. The tests were run  
199 interspersed with the clinical samples across 2 days (20 October 2021 and 21 October 2021).  
200 Gazelle Covid-19 test showed high inter-operator test operator agreement. Gazelle also showed  
201 100% accuracy on all the contrived sample testing.

202

## 203 **DISCUSSION**

204

205 Rapid-result testing for SARS-CoV-2 has value in many clinical settings that may not have  
206 access to specialized laboratory equipment or personnel and have a need for immediate decision-  
207 making or counseling the patient according to the results obtained. Here we describe the  
208 performance of Gazelle Covid-19 test for the qualitative detection of SARS-CoV-2 in nasal swab  
209 samples from symptomatic subjects. Gazelle Covid-19 test demonstrated high diagnostic  
210 potential with low false positive/negative rates and a detection accuracy of 99.4% compared to  
211 the RT-PCR. Gazelle Covid-19 test meets the criteria recommended in WHO interim guidance  
212 for diagnosis of SARS-CoV-2 infection (at least 80% sensitivity and 97% specificity) with rapid  
213 antigen assays [13].

214

215 An optimal Covid-19 test would detect replicating or transmissible virus, avoiding prolonged  
216 positivity of RT-PCR after infectiousness has resolved. There is currently no gold standard test

217 that identifies infectious subjects with replicating or transmissible virus. SARS-CoV-2  
218 nucleocapsid antigen is generally detectable in nasal swabs during the acute phase of infection  
219 [14]. Positive results indicate the presence of viral antigens, but clinical correlation with patient  
220 history and other diagnostic information is necessary to determine disease status. In this context,  
221 antigen testing has been shown to have higher accuracy among specimens with positive viral  
222 culture, correlating with the period when infectious virus is present [15].

223 Persons who know their positive test result can isolate sooner, and where appropriate contact  
224 tracing can be initiated sooner and be more effective. Asymptomatic SARS-CoV-2 infected  
225 subjects were not included in the study, and lower viral loads are likely to reduce sensitivity  
226 relative to PCR, though these cases are also less likely to transmit (REF). A study to assess the  
227 performance of Gazelle Covid-19 test in an asymptomatic population is currently underway. This  
228 study adds to the growing evidence of the performance of different rapid SARS-CoV-2 antigen  
229 detections, especially in the community settings. Gazelle Covid-19 test is easy to perform with  
230 minimal training or previous laboratory testing experience and is thus a feasible solution to  
231 implement at sites requiring a POC solution. Inter-operator test operator agreement in the target  
232 clinical population and environment indicated that the device operation and the results are  
233 reproducible.

234  
235 This study has some limitations. subjects with invalid results were not able to be retested because  
236 participants left the facility before test results were available. A total of 2.6% of the initial  
237 Gazelle Covid-19 test results were either invalid or canceled and would have required patient  
238 retesting in accordance with the IFU. Re-collection of samples and retesting would be expected  
239 to further reduce the invalid rate, but this was not possible during our study. Discrepant results  
240 observed between the Gazelle Covid-19 test and reference RT-PCR could not be further  
241 clarified, as further samples were not available for retesting.

242  
243  
244 In summary, herein we have shown that the Gazelle Covid-19 test using a nasal swab collection  
245 method is highly accurate and has close concordance with RT-PCR based assay for detection of  
246 SARS-CoV-2 in a POC setting. Gazelle Covid-19 test has potential to quickly and effectively



247 screen all symptomatic patients suspected of COVID-19 at POC, enabling rapid detection and  
248 isolation of people most likely to pose an infectious risk.

249

250

#### 251 **DATA AVAILABILITY STATEMENT**

252 The datasets generated during and/or analyzed during the current study are available from the  
253 corresponding author on reasonable request.

254

#### 255 **ETHICS STATEMENT**

256 Institutional Review Board approval was obtained by the sponsor before starting the study in the  
257 United States (WCG IRB Tracking number: 20212857). Study protocol from India was approved  
258 by the Ethics Committee of International Institute of Sleep Sciences (Reg No:  
259 ECR/177/Indt/MH-2014/RR-19). Informed consents were obtained from all study participants.

260

#### 261 **FUNDING**

262 The funding for the study was provided by Hemex Health, Inc., USA.

263

#### 264 **ACKNOWLEDGMENTS**

265 None

266

#### 267 **CONFLICT OF INTEREST**

268 ROG and KT were hired as consultants by Hemex Health to execute this study. AM is a board  
269 member of HemexDx, a subsidiary of Hemex Health in India.

270

#### 271 **REFERENCES**

272

- 273 1. World Health Organization (WHO). WHO Director-General's opening remarks at the  
274 media briefing on COVID-19: 11 March 2020. Published March 11, 2020. Accessed  
275 March 11, 2020. [https://www.who.int/dg/speeches/detail/who-director-general-s-  
276 opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020).

- 277 2. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical  
278 samples. *Lancet Infect Dis* 2020;20:411–2.
- 279 3. Reynard C, Allen JA, Shinkins B, Prestwich G, Goves J, Davies K, Body R. COVID-19  
280 rapid diagnostics: practice review. *Emergency Medicine Journal*. 2022 Jan 1;39(1):70-6.
- 281 4. Kretzschmar ME, Rozhnova G, Bootsma MC, van Boven M, van de Wijgert JH, Bonten  
282 MJ. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a  
283 modelling study. *The Lancet Public Health*. 2020 Aug 1;5(8):e452-9.
- 284 5. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ,  
285 Parker R. 2020. Test sensitivity is secondary to frequency and turnaround time for  
286 COVID-19 surveillance. *Science advances*. 2021 Jan 1;7(1):eabd5393.
- 287 6. Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jatun K, Greub G. Diagnostic  
288 strategies for SARS-CoV-2 infection and interpretation of microbiological results.  
289 *Clinical Microbiology and Infection*. 2020 Sep 1;26(9):1178-82.
- 290 7. Owusu D, Pomeroy MA, Lewis NM, Wadhwa A, Yousaf AR, Whitaker B, et al.  
291 Persistent SARS-CoV-2 RNA Shedding without Evidence of Infectiousness: A Cohort  
292 Study of Individuals with COVID-19. *J Infect Dis* 2021; jiab107.
- 293 8. World Health Organization. 2020. Global research collaboration for infectious disease  
294 preparedness—COVID 19: Public Health Emergency of International Concern (PHEIC).  
295 Global research and innovation forum: towards a research roadmap, 02/11/2020–  
296 02/12/2020. World Health Organization, Geneva, Switzerland.  
297 [https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-](https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum)  
298 [international-concern-\(pheic\)-global-research-and-innovation-forum](https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum).
- 299 9. Laboratory Testing for Coronavirus Disease 2019 (COVID-19) in Suspected Human  
300 Cases: Interim Guidance (World Health Organization, 2 March 2020);  
301 <https://apps.who.int/iris/handle/10665/331329>.
- 302 10. Shrivastava S, Patel M, Kumar R, Gwal A, Uikey R, Tiwari SK, Verma AK, Thota P, Das A,  
303 Bharti PK, Shanmugam R. Evaluation of Microchip-Based Point-Of-Care Device  
304 “Gazelle” for Diagnosis of Sickle Cell Disease in India. *Frontiers in Medicine*. 2021;8.
- 305 11. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole  
306 C, Schlesselman JJ, Egger M. STROBE Initiative. Strengthening the Reporting of

307 Observational Studies in Epidemiology (STROBE): Explanation and elaboration. PLoS  
308 Med. 2007, 4, e297.

309 12. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, Irwig L, Levine  
310 D, Reitsma JB, de Vet HC, et al. STARD 2015 guidelines for reporting diagnostic  
311 accuracy studies: Explanation and elaboration. BMJ Open 2016, 6, e012799.

312 13. World Health Organisation Advice on the Use of Point-of-Care Immunodiagnostic Tests  
313 for COVID-19. 2020. [https://www.who.int/news-room/commentaries/detail/advice-on-](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)  
314 [the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)

315 14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z,  
316 Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J,  
317 Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients  
318 infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506.

319 15. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two  
320 Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020.  
321 <https://www.cdc.gov/mmwr/volumes/70/wr/mm7003e3.htm>

322

## 323 AUTHOR CONTRIBUTIONS

324

325 AM, AG and PK helped with the planning and execution of clinical study in India and BS, ROG,  
326 KT and RRF helped with the planning and execution of the clinical study in the US. AG, PK,  
327 BS, ROG and KT helped with subject recruitment, nasal swab collection, and testing. All the  
328 authors authored and edited the manuscript and helped in preparing the tables, figures, figure  
329 captions, and supplementary information.

330

331

332

333

334

335

336

337

338 **Table 1.** Results of Gazelle Covid-19 Test in comparison to RT-PCR

		<b>RT-PCR confirmed COVID-19</b>		
<b>United States</b>				
		Positive	Negative	Total
Gazelle Covid-19 Test	Positive	44	1	45
	Negative	2	381	383
	Total	46	382	428
<b>India</b>				
		Positive	Negative	Total
Gazelle Covid-19 Test	Positive	85	3	88
	Negative	3	967	970
	Total	88	970	1058
<b>Combined</b>				
		Positive	Negative	Total
Gazelle Covid-19 Test	Positive	129	4	133
	Negative	5	1348	1353
	Total	134	1352	1486

339

340

341 **Table 2.** Performance of Gazelle Covid-19 Test in comparison to RT-PCR

	<b>United States</b>	<b>India</b>	<b>Combined % (n/N)</b>
Sensitivity	95.7% (44/45)	96.6% (85/88)	96.3% (129/134)
Specificity	99.7% (381/383)	99.7% (967/970)	99.7% (1348/1352)
Positive Predictive Value (PPV)	99.3% (425/428)	99.7% (967/970)	97.0% (129/133)

Negative Predictive Value (NPV)	97.8% (44/45)	96.6% (85/88)	99.6% (1348/1353)
Accuracy	99.5% (381/383)	99.7% (967/970)	99.4% (1477/1486)

342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364

365  
366


### Figure 1. Gazelle Covid-19 Reader and interpretation of results

FIGURE 1a




Gazelle device with lateral flow immunoassay


FIGURE 1b



**POSITIVE RESULT-** If both the quality control (white) line and the detection (red) line appear, COVID-19 has been detected and the result is positive.



**NEGATIVE RESULT-** If there is only a quality control (White) line, this indicates that COVID-19 has not been detected and the result is negative.




**TEST PROBLEM ENCOUNTERED-** If the "TEST PROBLEM ENCOUNTERED" message was received, check the cassette to see if placed correctly. If not, place in correct orientation and rerun test.

367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378

379  
380  
381

**Figure 2.** Patient screening and enrolment flowchart



382